139 related articles for article (PubMed ID: 36288088)
1. Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer's Disease.
Sun Y; Xu L; Shao H; Quan D; Mo Z; Wang J; Zhang W; Yu J; Zhuang C; Xu K
J Med Chem; 2022 Nov; 65(21):14957-14969. PubMed ID: 36288088
[TBL] [Abstract][Full Text] [Related]
2. Targeting Receptor-Interacting Protein Kinase 1 by Novel Benzothiazole Derivatives: Treatment of Acute Lung Injury through the Necroptosis Pathway.
Zhang X; Han Q; Hou R; Xu L; Zhang W; Xing C; Xue L; Zhuang C
J Med Chem; 2023 Apr; 66(7):5261-5278. PubMed ID: 36908007
[TBL] [Abstract][Full Text] [Related]
3. Identification of the Raf kinase inhibitor TAK-632 and its analogues as potent inhibitors of necroptosis by targeting RIPK1 and RIPK3.
Chen X; Zhuang C; Ren Y; Zhang H; Qin X; Hu L; Fu J; Miao Z; Chai Y; Liu ZG; Zhang H; Cai Z; Wang HY
Br J Pharmacol; 2019 Jun; 176(12):2095-2108. PubMed ID: 30825190
[TBL] [Abstract][Full Text] [Related]
4. Profiling of the chemical space on the phenyl group of substituted benzothiazole RIPK3 inhibitors.
Xu Y; Liang C; Zhang W; Yu J; Xing C; Liu H; Zhuang C
Bioorg Chem; 2023 Feb; 131():106339. PubMed ID: 36599218
[TBL] [Abstract][Full Text] [Related]
5. Discovery of 4-amino-1,6-dihydro-7H-pyrrolo[2,3-d]pyridazin-7-one derivatives as potential receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitors.
Zhang C; Chen Y; Li Y; Shi N; Teng Y; Li N; Tang M; Ma Z; Deng D; Chen L
Eur J Med Chem; 2024 Feb; 265():116076. PubMed ID: 38171150
[TBL] [Abstract][Full Text] [Related]
6. Cognitive enhancing effects of pazopanib in D‑galactose/ovariectomized Alzheimer's rat model: insights into the role of RIPK1/RIPK3/MLKL necroptosis signaling pathway.
Abdelhady R; Younis NS; Ali O; Shehata S; Sayed RH; Nadeem RI
Inflammopharmacology; 2023 Oct; 31(5):2719-2729. PubMed ID: 37458952
[TBL] [Abstract][Full Text] [Related]
7. Novel insights into RIPK1 as a promising target for future Alzheimer's disease treatment.
Li S; Qu L; Wang X; Kong L
Pharmacol Ther; 2022 Mar; 231():107979. PubMed ID: 34480965
[TBL] [Abstract][Full Text] [Related]
8. Hyperphosphorylated tau mediates neuronal death by inducing necroptosis and inflammation in Alzheimer's disease.
Dong Y; Yu H; Li X; Bian K; Zheng Y; Dai M; Feng X; Sun Y; He Y; Yu B; Zhang H; Wu J; Yu X; Wu H; Kong W
J Neuroinflammation; 2022 Aug; 19(1):205. PubMed ID: 35971179
[TBL] [Abstract][Full Text] [Related]
9. Insight from Linker Investigations: Discovery of a Novel Phenylbenzothiazole Necroptosis Inhibitor Targeting Receptor-Interacting Protein Kinase 1 (RIPK1) from a Phenoxybenzothiazole Compound with Dual RIPK1/3 Targeting Activity.
Fang JJ; Yao HZ; Zhuang C; Chen FE
J Med Chem; 2023 Nov; 66(22):15288-15308. PubMed ID: 37917221
[TBL] [Abstract][Full Text] [Related]
10. Roles of receptor-interacting protein kinase 1 in SH-SY5Y cells with beta amyloid-induced neurotoxicity.
Chan HH; Leong CO; Lim CL; Koh RY
J Cell Mol Med; 2022 Mar; 26(5):1434-1444. PubMed ID: 35106914
[TBL] [Abstract][Full Text] [Related]
11. Discovery of potent necroptosis inhibitors targeting RIPK1 kinase activity for the treatment of inflammatory disorder and cancer metastasis.
Hou J; Ju J; Zhang Z; Zhao C; Li Z; Zheng J; Sheng T; Zhang H; Hu L; Yu X; Zhang W; Li Y; Wu M; Ma H; Zhang X; He S
Cell Death Dis; 2019 Jun; 10(7):493. PubMed ID: 31235688
[TBL] [Abstract][Full Text] [Related]
12.
Zhang H; Xu L; Qin X; Chen X; Cong H; Hu L; Chen L; Miao Z; Zhang W; Cai Z; Zhuang C
J Med Chem; 2019 Jul; 62(14):6665-6681. PubMed ID: 31095385
[TBL] [Abstract][Full Text] [Related]
13. Analysis on benzothiazole necroptosis inhibitors with chiral substitutions in the solvent-accessible region of RIP kinase domain.
Shao H; Xu L; Li G; Wang S; Han T; Zhuang C
Bioorg Chem; 2023 Aug; 137():106647. PubMed ID: 37270986
[TBL] [Abstract][Full Text] [Related]
14. Necroptosis inhibition as a therapy for Niemann-Pick disease, type C1: Inhibition of RIP kinases and combination therapy with 2-hydroxypropyl-β-cyclodextrin.
Cougnoux A; Clifford S; Salman A; Ng SL; Bertin J; Porter FD
Mol Genet Metab; 2018 Dec; 125(4):345-350. PubMed ID: 30392741
[TBL] [Abstract][Full Text] [Related]
15. Molecular and functional characteristics of receptor-interacting protein kinase 1 (RIPK1) and its therapeutic potential in Alzheimer's disease.
Pati S; Singh Gautam A; Dey M; Tiwari A; Kumar Singh R
Drug Discov Today; 2023 Dec; 28(12):103750. PubMed ID: 37633326
[TBL] [Abstract][Full Text] [Related]
16. Discovery, optimization and evaluation of isothiazolo[5,4-b]pyridine derivatives as RIPK1 inhibitors with potent in vivo anti-SIRS activity.
Hao Y; Yang C; Shu C; Li Z; Xia K; Wu S; Ma H; Tian S; Ji Y; Li J; He S; Zhang X
Bioorg Chem; 2022 Dec; 129():106051. PubMed ID: 36115309
[TBL] [Abstract][Full Text] [Related]
17. FKBP12 mediates necroptosis by initiating RIPK1-RIPK3-MLKL signal transduction in response to TNF receptor 1 ligation.
Wang Z; Feng J; Yu J; Chen G
J Cell Sci; 2019 May; 132(10):. PubMed ID: 31028177
[TBL] [Abstract][Full Text] [Related]
18. RIPK1 can function as an inhibitor rather than an initiator of RIPK3-dependent necroptosis.
Kearney CJ; Cullen SP; Clancy D; Martin SJ
FEBS J; 2014 Nov; 281(21):4921-34. PubMed ID: 25195660
[TBL] [Abstract][Full Text] [Related]
19. RIPK1 counteracts ZBP1-mediated necroptosis to inhibit inflammation.
Lin J; Kumari S; Kim C; Van TM; Wachsmuth L; Polykratis A; Pasparakis M
Nature; 2016 Dec; 540(7631):124-128. PubMed ID: 27819681
[TBL] [Abstract][Full Text] [Related]
20. Targeting Necroptosis as a Promising Therapy for Alzheimer's Disease.
Zhao W; Liu Y; Xu L; He Y; Cai Z; Yu J; Zhang W; Xing C; Zhuang C; Qu Z
ACS Chem Neurosci; 2022 Jun; 13(12):1697-1713. PubMed ID: 35607807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
